iRen transforms the experience for people on peritoneal dialysis to make it simple, quick, and safe. iRen’s home dialysis platform combines new technologies for safe and effective Home Peritoneal Dialysis with the ability for providers and patients to collaborate in driving the best clinical outcomes.
iRen’s platform is FDA approved.
1 out of 10 people in the world experience kidney disease/failure and the most common treatment modality is in-clinic hemodialysis (88% of patients)
This means people spend most of their time traveling to or in treatment. The 12% of patients who opt for home dialysis, are still confined to their homes for hours every day. Using these data, iRen’s team identified the need for a significant disruption of traditional treatments.
iRen Medical’s mission is to transform the dialysis experience.
We are thrilled and excited to share that iRen-MEDICAL has been recognized by the Israel Innovation Authority (IIA) as a recipient of a significant grant to further our commitment to innovation and sustainable solutions for people requiring dialysis and their care givers. This grant serves as additional testimony to the immense potential of our groundbreaking…
We are thrilled to be one of the 13 entrepreneurs selected to present their company at Calcalist’s 6th Annual Mind the Tech NY, to be held 5-7 November 2023. We will be showcasing iRen Medical’s breakthrough Digital Dialysis Clinic solution which enables novel, transformational dialysis for safe self-care at home, at the office, or while…
We are happy to announce that liberDi is rebranding and will be named iRen-MEDICAL moving forward. The change in name follows receipt of FDA clearance and in advance of our marketing efforts in the US. Rebranding with the name iRen-MEDICAL will assist us in differentiating our unique company, product and services in the dialysis market.…
liberDi is extremely excited to have its abstract accepted for the poster presentation at the upcoming American Society for Nephrology – ASN Kidney Week 2023 taking place November 1-5, in Philadelphia. Our poster presentation outlines how liberDi’s Intelligent Dialysis Assistant (iDA), a new electronic automated ambulatory PD exchange device (part of liberDi’s Digital Dialysis Clinic)…
We are pleased to share an article that was previously published on Israel21c (www.israel21c.org) to commemorate World Kidney Day on March 9th in order to raise awareness about the various kidney diseases. The article discusses a new kidney care innovation that could greatly benefit dialysis patients. Patients with kidney failure have traditionally have to go…
At MDI EXPO 2023, liberDi shared its experience obtaining FDA clearance for its Digital Dialysis Clinic for Home Use with the Israeli medical device community.
Misgav, Israel, XX January 2023 – liberDi Ltd., a portfolio company of The Trendlines Group Ltd. (“Trendlines”) (SGX: 42T; OTCQX: TRNLY), announced today that it has received regulatory clearance from the United States Food and Drug Administration (FDA) for its Digital Dialysis Clinic, which allows patients to perform dialysis at home or at the workplace,…
liberDi is now one of 4 startups competing for the a prize of up to 100k ILS and access to medical research by Medimor and Poriya. Finals will be held October 25th. Details here: https://www.meetup.com/mHealth-Israel/events/278161062/
Out of more than 70 Israeli medtech startups applying, liberDi, alongside 7 other startups made it to the semi-finals. The companies will be competing for financial prizes of up to 100K ILS courtesy of Medimor and Poriya and for facilitated access to medical research.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.